Clinical applications of microRNAs

View/ Open
Published Version
https://doi.org/10.12688/f1000research.2-136.v3Metadata
Show full item recordCitation
Hydbring, Per, and Gayane Badalian-Very. 2013. “Clinical applications of microRNAs.” F1000Research 2 (1): 136. doi:10.12688/f1000research.2-136.v3. http://dx.doi.org/10.12688/f1000research.2-136.v3.Abstract
MicroRNAs represent a class of small RNAs derived from polymerase II controlled transcriptional regions. The primary transcript forms one or several bulging double stranded hairpins which are processed by Drosha and Dicer into hetero-duplexes. The targeting microRNA strand of the duplex is incorporated into the RNA Induced Silencing Complex from where it silences up to hundreds of mRNA transcript by inducing mRNA degradation or blocking protein translation. Apart from involvement in a variety of biological processes, microRNAs were early recognized for their potential in disease diagnostics and therapeutics. Due to their stability, microRNAs could be used as biomarkers. Currently, there are microRNA panels helping physicians determining the origins of cancer in disseminated tumors. The development of microRNA therapeutics has proved more challenging mainly due to delivery issues. However, one drug is already in clinical trials and several more await entering clinical phases. This review summarizes what has been recognized pre-clinically and clinically on diagnostic microRNAs. In addition, it highlights individual microRNA drugs in running platforms driven by four leading microRNA-therapeutic companies.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3917658/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:12064517
Collections
- HMS Scholarly Articles [17293]
Contact administrator regarding this item (to report mistakes or request changes)